2012Scientia MedicaOpen access

New alternatives for protocols with murine models of asthma [Abstract in English]

Camila de Oliveira Parreira, Andréa Mendonça Rodrigues, Lucien Peroni Gualdi, Raquel Giacomelli Cao, Rodrigo Godinho de Souza, Ana Cláudia Pereira, Nailê Karine Nuñez, Álisson Passos Schleich, Mauro Henrique Moraes Vargas, Paulo Márcio Pitrez

Open full text 0 citations

Abstract

AIMS: To test alternative protocols using animal models of acute and chronic asthma, with features closer to human disease, using ovalbumin without adjuvant. METHODS: Adult female BALB/c mice were used and divided into groups according to sensitization with ovalbumin. The acute model used two doses of ovalbumin subcutaneously without adjuvant, on days 0 and 7, and after intranasal challenge for consecutives three days, compared with a standard protocol using three doses of ovalbumin for sensitization. The chronic model also used ovalbumin subcutaneously for sensitization, adjuvant-free, on days 0 and 14, and after intranasal challenge, for eight consecutive weeks. Total and differential cell counts from bronchoalveolar lavage and histopathology of the lungs were performed 24 hours after the last ovalbumin challenge. RESULTS: In both models of protocols studied, acute and chronic, we have observed similar allergic pulmonary response between the groups. Cell counts and histological analysis of lung tissue showed no significant difference between groups. CONCLUSIONS: Use of sensitization in murine model with ovalbumin subcutaneously, with no adjuvant (alum), resulted in an expected allergic pulmonary response, with predominant eosinophils. These protocols may be a future option to animal models of asthma closer to the human disease, both in the acute and chronic patterns.

About this research paper

What this paper is about

AIMS: To test alternative protocols using animal models of acute and chronic asthma, with features closer to human disease, using ovalbumin without adjuvant. METHODS: Adult female BALB/c mice were used and divided into groups according to sensitization with ovalbumin. The acute model used two doses of ovalbumin subcutaneously without adjuvant, on days 0 and 7, and after intranasal challenge for consecutives three days, compared with a standard protocol using three doses of ovalbumin for sensitization. The chronic model also used ovalbumin subcutaneously for sensitization, adjuvant-free, on days 0 and 14, and after intranasal challenge, for eight consecutive weeks. Total and differential cell counts from bronchoalveolar lavage and histopathology of the lungs were performed 24 hours after the last ovalbumin challenge. RESULTS: In both models of protocols studied, acute and chronic, we have observed similar allergic pulmonary response between the groups. Cell counts and histological analysis of lung tissue showed no significant difference between groups. CONCLUSIONS: Use of sensitization in murine model with ovalbumin subcutaneously, with no adjuvant (alum), resulted in an expected allergic pulmonary response, with predominant eosinophils. These protocols may be a future option to animal models of asthma closer to the human disease, both in the acute and chronic patterns.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

AIMS: To test alternative protocols using animal models of acute and chronic asthma, with features closer to human disease, using ovalbumin without adjuvant. METHODS: Adult female BALB/c mice were used and divided into groups according to sensitization with ovalbumin. The acute model used two doses of ovalbumin subcutaneously without adjuvant, on days 0 and 7, and after intranasal challenge for consecutives three days, compared with a standard protocol using three doses of ovalbumin for sensitization. The chronic model also used ovalbumin subcutaneously for sensitization, adjuvant-free, on days 0 and 14, and after intranasal challenge, for eight consecutive weeks. Total and differential cell counts from bronchoalveolar lavage and histopathology of the lungs were performed 24 hours after the last ovalbumin challenge. RESULTS: In both models of protocols studied, acute and chronic, we have observed similar allergic pulmonary response between the groups. Cell counts and histological analysis of lung tissue showed no significant difference between groups. CONCLUSIONS: Use of sensitization in murine model with ovalbumin subcutaneously, with no adjuvant (alum), resulted in an expected allergic pulmonary response, with predominant eosinophils. These protocols may be a future option to animal models of asthma closer to the human disease, both in the acute and chronic patterns.

Key concepts: Ovalbumin, Medicine, Sensitization, Adjuvant, Bronchoalveolar lavage, Asthma, Immunology, Lung

Related papers

Back to paper searchBrowse research topicsOriginal source
New alternatives for protocols with murine models of asthma [Abstract in English] — Research Paper | ScholarLens